These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36681161)

  • 1. Multi-omics profiling of cholangiocytes reveals sex-specific chromatin state dynamics during hepatic cystogenesis in polycystic liver disease.
    Ji R; Chen J; Xie Y; Dou X; Qing B; Liu Z; Lu Y; Dang L; Zhu X; Sun Y; Zheng X; Zhang L; Guo D; Chen Y
    J Hepatol; 2023 Apr; 78(4):754-769. PubMed ID: 36681161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.
    Masyuk AI; Masyuk TV; Lorenzo Pisarello MJ; Ding JF; Loarca L; Huang BQ; LaRusso NF
    Hepatology; 2018 Mar; 67(3):1088-1108. PubMed ID: 29023824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.
    Masyuk T; Masyuk A; Trussoni C; Howard B; Ding J; Huang B; LaRusso N
    JHEP Rep; 2021 Oct; 3(5):100345. PubMed ID: 34568801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease.
    Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Perugorria MJ; Azkargorta M; Elortza F; Martinez-Chantar ML; Aspichueta P; Marzioni M; Bujanda L; Drenth JPH; Banales JM
    United European Gastroenterol J; 2021 Sep; 9(7):848-859. PubMed ID: 34310849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
    Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Santos-Laso A; Azkargorta M; Elortza F; Martinez-Chantar ML; Perugorria MJ; Aspichueta P; Marzioni M; LaRusso NF; Bujanda L; Drenth JPH; Banales JM
    J Hepatol; 2021 Feb; 74(2):394-406. PubMed ID: 32950589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenomic Evaluation of Cholangiocyte Transforming Growth Factor-β Signaling Identifies a Selective Role for Histone 3 Lysine 9 Acetylation in Biliary Fibrosis.
    Aseem SO; Jalan-Sakrikar N; Chi C; Navarro-Corcuera A; De Assuncao TM; Hamdan FH; Chowdhury S; Banales JM; Johnsen SA; Shah VH; Huebert RC
    Gastroenterology; 2021 Feb; 160(3):889-905.e10. PubMed ID: 33058867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.
    Gradilone SA; Habringer S; Masyuk TV; Howard BN; Masyuk AI; Larusso NF
    Am J Pathol; 2014 Mar; 184(3):600-8. PubMed ID: 24434010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycystic Liver Disease: Advances in Understanding and Treatment.
    Masyuk TV; Masyuk AI; LaRusso NF
    Annu Rev Pathol; 2022 Jan; 17():251-269. PubMed ID: 34724412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.
    Masyuk TV; Masyuk AI; Lorenzo Pisarello M; Howard BN; Huang BQ; Lee PY; Fung X; Sergienko E; Ardecky RJ; Chung TDY; Pinkerton AB; LaRusso NF
    Hepatology; 2017 Oct; 66(4):1197-1218. PubMed ID: 28543567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
    Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
    J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Targets in Polycystic Liver Disease.
    Masyuk TV; Masyuk AI; LaRusso NF
    Curr Drug Targets; 2017; 18(8):950-957. PubMed ID: 25915482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGR5 in the Cholangiociliopathies.
    Masyuk TV; Masyuk AI; LaRusso NF
    Dig Dis; 2015; 33(3):420-5. PubMed ID: 26045278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
    Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
    Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets.
    Santos-Laso A; Izquierdo-Sanchez L; Rodrigues PM; Huang BQ; Azkargorta M; Lapitz A; Munoz-Garrido P; Arbelaiz A; Caballero-Camino FJ; Fernández-Barrena MG; Jimenez-Agüero R; Argemi J; Aragon T; Elortza F; Marzioni M; Drenth JPH; LaRusso NF; Bujanda L; Perugorria MJ; Banales JM
    Liver Int; 2020 Jul; 40(7):1670-1685. PubMed ID: 32378324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into targeting hepatic cystogenesis in autosomal dominant polycystic liver and kidney disease.
    Barten TRM; Bernts LHP; Drenth JPH; Gevers TJG
    Expert Opin Ther Targets; 2020 Jun; 24(6):589-599. PubMed ID: 32250187
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases.
    Urribarri AD; Munoz-Garrido P; Perugorria MJ; Erice O; Merino-Azpitarte M; Arbelaiz A; Lozano E; Hijona E; Jiménez-Agüero R; Fernandez-Barrena MG; Jimeno JP; Marzioni M; Marin JJ; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Banales JM
    Gut; 2014 Oct; 63(10):1658-67. PubMed ID: 24436140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical manifestation, epidemiology, genetic basis, potential molecular targets, and current treatment of polycystic liver disease.
    Mahboobipour AA; Ala M; Safdari Lord J; Yaghoobi A
    Orphanet J Rare Dis; 2024 Apr; 19(1):175. PubMed ID: 38671465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
    Masyuk TV; Masyuk AI; Torres VE; Harris PC; Larusso NF
    Gastroenterology; 2007 Mar; 132(3):1104-16. PubMed ID: 17383431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
    Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
    Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
    Spirli C; Mariotti V; Villani A; Fabris L; Fiorotto R; Strazzabosco M
    J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.